    T75093WO                                                      BOEHMERT & BOEHMERT

                                           CLAIMS

    . A method for predicting or diagnosing a refractory shock in a subject that either runs into shock or
      that has developed shock, wherein said method is comprising the steps:
      0 determining the level of DPP3 in a sample of bodily fluid of said subject,
      0 compaiing said level of determined DPP3 to a predetermined threshold,
      wherein said subject is predicted to run into refractory shock or is diagnosed as having refractory
          shock if said determined level of DPP3 is above said predetermined threshold.

10 . A method for predicting or diagnosing a refractory shock in a subject that either runs into shock or
           that has developed shock according to claim 1, wherein said shock is selected from the group
           compiising shock due to hypovolemia, cardiogenic shock, obstructive shock and distiibutive shock,
            in particular cardiogenic shock or septic shock.

15  . A method for predicting or diagnosing a refractory shock in a subject that either runs into shock or

    that has developed shock according to claim 1 or 2, wherein said shock is a vasopressor-resistant

    shock.

    . A method for predicting or diagnosing a refractory shock in a subject that either runs into shock or

20  that has developed shock according to claims 1 to 3, wherein

    0 in case of cardiogenic shock said subject may have suffered an acute coronary syndrome (e.g.

    acute myocardial infarction) or wherein said subject has heart failure (e.g. acute decompensated

    heart failure), myocarditis, arrhythmia, cardiomyopathy, valvular heart disease, aOItic dissection

    With acute aOItic stenosis, traumatic chordal rupture or massive pulmonary embolism, or

25  0 in case of hypovolemic shock said subject may have suffered a hemorrhagic disease including

    gastrointestinal bleed, trauma, vascular etiologies (e.g. ruptured abdominal aOItic aneurysm,

    tumor eroding into a major blood vessel) and spontaneous bleeding in the setting of

    anticoagulant use or a non-hemorrhagic disease including vomiting, diarrhea, renal loss, skin

    losses/insensible losses (e.g. bums, heat stroke) or third-space loss in the setting of pancreatitis,

30  cirrhosis, intestinal obstruction, trauma, or

    0 in case of obstructive shock said patient may have suffered a cardiac tamponade, tension

    pneumothoraX, pulmonary embolism or aOItic stenosis, or

    0 in case of distiibutive shock said patient may have septic shock, neurogenic shock, anaphylactic

    shock or shock due to adrenal c1isis.

35
                                                                    101

    . A method for predicting or diagnosing a refractory shock in a subject that either runs into shock or
      that has developed shock according to claims 1 to 4, wherein said method is used for initiation
      and/or termination and/ or stratification and/or guidance of treatment.

    . A method for predicting or diagnosing a refractory shock in a subject that either runs into shock or
      that has developed shock according to any of claims 1 to 5, wherein a treatment is initiated and/or
      maintained and/or Withheld and/ or terminated if said determined level of DPP3 is above said
      predetermined threshold.

10 . A method for predicting or diagnosing a refractory shock in a subject that either runs into shock or
           that has developed shock according to claim 6, wherein said treatment is selected from the group of
           vasopressors, Angiotensin-Receptor-Agonists and/or precursors thereof, inhibitors of the DPP3
            activity and anti-adrenomedullin antibodies or anti-adrenomedullin antibody fragments.

15  . A method for predicting or diagnosing a refractory shock in a subject that either runs into shock or

    that has developed shock according to any of claims 1 to 7, wherein either the level of DPP3

    protein and/or the level of active DPP3 is determined and compared to a predetermined threshold,

    wherein the level of DPP3 is determined by contacting said sample of bodily fluid With a capture

    binder that binds specifically to DPP3.

20

    . A method for predicting or diagnosing a refractory shock in a subject that either runs into shock or

    that has developed shock according to any of claims 1 to 8, wherein a treatment With Angiotensin-

    Receptor-Agonists and/ or precursors thereof and/or inhibitors of the DPP3 activity is initiated

    and/or continued When the level of DPP3 in said sample is above a ceitain threshold and/or

25  wherein a treatment With vasopressors is Withheld and/ or terminated if said determined level of

    DPP3 is above said predetermined threshold.

    10. A method for predicting or diagnosing a refractory shock in a subject that either runs into shock or

    that has developed shock according to any of claims 1 to 9, wherein a treatment With vasopressors

30  is initiated and/or continued When the level of DPP3 in said sample is below a ceItain threshold

    and/or wherein a treatment With Angiotensin-Receptor-Agonists and/ or precursors thereof and/or

    inhibitors of the DPP3 activity is Withheld and/ or terminated if the said determined level of DPP3

    is below said predetermined threshold.
                                                                      102

    11A method for predicting or diagnosing a refractory shock in a subject that either runs into shock or
       that has developed shock according to claim 9, wherein in addition the level of Pro-adrenomedullin
       or fragments thereof is determined and wherein treatment With an anti-ADM antibody or anti-ADM
       antibody fragment is initiated and/or continued When the level of Pro-adrenomedullin or fragments
       thereof in said sample is above a ceItain threshold and/or wherein a treatment With an anti-ADM
       antibody or anti-ADM antibody fragment is Withheld and/ or terminated if the said determined
       level of Pro-adrenomedullin or fragments thereof is below said predetermined threshold.

    12A method for predicting or diagnosing a refractory shock in a subject that either runs into shock or

10  that has developed shock according to claim 9, wherein treatment With an anti-ADM antibody or

    anti-ADM antibody fragment and/or Angiotensin-Receptor-Agonists and/ or precursors thereof

    and/or inhibitors of the DPP3 activity is initiated and/or continued if the level of Pro-

    adrenomedullin or fragments thereof in said sample is above a ceItain threshold and said

    determined level of DPP3 is above said predetermined threshold of DPP3.

15

        13.Vasopressor for use in therapy of shock in a subject that either runs into shock or that has
            developed shock, wherein said subject has a level of DPP3 in a sample of bodily fluid of said
            subject that is below a predetermined threshold, When determined by a method according to any of
             claims 1 -- 11.

20

    14.1nhibitor of the activity of DPP3 for use in therapy of shock in a subject that either runs into shock

    or that has developed shock, wherein said subject has a level of DPP3 in a sample of bodily fluid of

    said subject that is above a predetermined threshold When determined by a method according to

    any of claims 1 -- 11, wherein the inhibitor of the activity of DPP3 is selected from the group

25  compiising anti-DPP3 antibody or anti-DPP3 antibody fragment or anti-DPP3 non-Ig scaffold.

        15.1nhibitor of the activity of DPP3 for use in therapy of shock in a subject that either runs into shock
            or that has developed shock according to claim 14, wherein said inhibitor is administered in
            combination With an Angiotensin-Receptor-Agonist and/or precursor thereof.

30

        16.1nhibitor of the activity of DPP3 for use in therapy of shock in a subject that either runs into shock
            or that has developed shock according to claim 15, wherein said Angiotensin-Receptor-Agonist
            and/ or precursor thereof is selected from the group comprising angiotensin I, angiotensin II,
            angiotensin III, angiotensin IV, in paiticular angiotensin II.

35
                                                                      103

    17.A method of treatment of shock in a subject that either runs into shock or that has developed shock,
       the method compiising administeiing vasopressor to said subject, wherein said subject has a level
       of DPP3 in a sample of bodily fluid of said subject that is below a predetermined threshold, When
       determined by a method according to any of claims 1 -- 11.

        18.Method of treatment of shock in a subject that either runs into shock or that has developed shock,
           the method compiising administeiing inhibitor of DPP3 activity to said subject, wherein said
            subject has a level of DPP3 in a sample of bodily fluid of said subject that is above a predetermined
           threshold When determined by a method according to any of claims 1 -- 11.

10

        19.Method of treatment of shock in a subject that either runs into shock or that has developed shock
            according to claim 18, the method compiising administeiing an inhibitor of DPP3 activity to said
            subject, wherein said inhibitor is administered in combination With an Angiotensin-Receptor-
           Agonist and/ or a precursor thereof.

15

    20.Method of treatment of shock in a subject that either runs into shock or that has developed shock

    according to claims 17-18, the method compiising administeiing Angiotensin-Receptor-Agonists

    and/ or precursors thereof and/or inhibitor of DPP3 activity to said subject, wherein the treatment

    With said Angiotensin-Receptor-Agonists and/or inhibitors of the DPP3 activity is initiated and/or

20  continued When the level of DPP3 in a sample of said subject is above a ceitain threshold and/or

    wherein a treatment With vasopressors is Withheld and/ or terminated if said determined level of

    DPP3 is above said predetermined threshold.

    21.Method of treatment of shock in a subject that either runs into shock or that has developed shock

    according to claims 17-18, the method comprising administeiing vasopressor to said subject,

    wherein the treatment With said vasopressors is initiated and/or continued When the level of DPP3

    in a sample of bodily fluid of said subject is below a ceitain threshold and/or wherein a treatment

    With Angiotensin-Receptor-Agonists and/ or precursors thereof and/or inhibitors of the DPP3

    activity is Withheld and/ or terminated if the said determined level of DPP3 is below said

30  predetermined threshold.

    22.Method of treatment of shock in a subject that either runs into shock or that has developed shock

    according to claim 19, the method comprising administeiing Angiotensin-Receptor-Agonists and/

    or precursors thereof and/or inhibitor of DPP3 activity to said subj ect, and wherein in addition the

35  level of Pro-adrenomedullin or fragments thereof is determined and wherein treatment With said
                              104

    anti-ADM antibody or anti-ADM antibody fragment is initiated and/or continued When the level of

    Pro-adrenomedullin or fragments thereof in said sample is above a ceItain threshold and/or wherein

    a treatment With an anti-ADM antibody or anti-ADM antibody fragment is Withheld and/ or

    terminated if the said determined level of Pro-adrenomedullin or fragments thereof is below said

5   predetermined threshold.

    23.Method of treatment of shock in a subject that either runs into shock or that has developed shock

    according to claim 20, the method compiising administeiing vasopressor to said subject, and

    wherein in addition the level of Pro-adrenomedullin or fragments thereof is determined and

10  wherein treatment With said anti-ADM antibody or anti-ADM antibody fragment is initiated and/or

    continued When the level of Pro-adrenomedullin or fragments thereof in said sample is above a

    ceitain threshold and/or wherein a treatment With an anti-ADM antibody or anti-ADM antibody

    fragment is Withheld and/ or terminated if the said determined level of Pro-adrenomedullin or

    fragments thereof is below said predetermined threshold.

15

    24.Method of treatment of shock in a subject that either runs into shock or that has developed shock

    according to claim 21 and 22, the method comprising administeiing anti-ADM antibody or anti-

    ADM antibody fragment to said subject, wherein in addition the level of Pro-adrenomedullin or

    fragments thereof is determined and wherein treatment With said anti-ADM antibody or anti-ADM

20  antibody fragment is initiated and/or continued When the level of Pro-adrenomedullin or fragments

    thereof in said sample is above a ceItain threshold and/or wherein a treatment With an anti-ADM

    antibody or anti-ADM antibody fragment is Withheld and/ or terminated if the said determined

    level of Pro-adrenomedullin or fragments thereof is below said predetermined threshold.

25 25A method for prognosing an outcome and/or the Iisk of an adverse event in a subject that has

    developed refractory shock, wherein said method is comprising the steps:

    0 determining the level of DPP3 in a sample of bodily fluid of said subject;

    0 compaiing said level of determined DPP3 to a predetermined threshold,

    0 correlating said level of DPP3 With said Iisk of an adverse event in said subject, wherein an

30  elevated level above a ceItain threshold is predictive for an enhanced risk of said adverse events

    or,

    0 correlating said level of DPP3 With success of a therapy or intervention in said subject, wherein

    a level below a ceItain threshold is predictive for a success of therapy or intervention.
